GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Revenue

SynAct Pharma AB (OSTO:SYNACT) Revenue : kr0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Revenue?

SynAct Pharma AB's revenue for the three months ended in Dec. 2023 was kr0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00 Mil. SynAct Pharma AB's Revenue per Share for the three months ended in Dec. 2023 was kr0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


SynAct Pharma AB Revenue Historical Data

The historical data trend for SynAct Pharma AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Revenue Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial - - - - -

SynAct Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SynAct Pharma AB's Revenue

For the Biotechnology subindustry, SynAct Pharma AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Revenue distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Revenue falls into.



SynAct Pharma AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynAct Pharma AB  (OSTO:SYNACT) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


SynAct Pharma AB Revenue Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SynAct Pharma AB (OSTO:SYNACT) Business Description

Traded in Other Exchanges
Address
Sheelevagen 2, Lund, SWE, 223 81
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines